On September 26, 2024 GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE platform, reported that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School and GT Biopharma’s Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY (Press release, GT Biopharma, SEP 26, 2024, View Source [SID1234646876]). Company management will also be participating in 1×1 meetings during the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

3rd Annual ROTH Healthcare Opportunities Conference – October 9, 2024
Title: Panel 4 – Focus: Hematologic malignancies
Date: Wednesday, October 9, 2024
Time: 1:15-1:55 pm ET
Participant: Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program at the University of Minnesota Medical School & Consulting Senior Medical Director, GT Biopharma

If you are interested in arranging a 1×1 meeting request with management, please contact your ROTH representative.